Source: Eur Respir J, 53 (4) 1802223; 10.1183/13993003.02223-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Matthew J. Martin, Tim W. Harrison. Is it time to move away from short-acting beta-agonists in asthma management?. Eur Respir J, 53 (4) 1802223; 10.1183/13993003.02223-2018

Member's Comments

No comment yet.

Related content which might interest you: Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease Year: 2007 Long-acting bronchodilators in COPD: where are we now and where are we going? Source: Breathe 2014; 10:110-120 Year: 2014 Is beta-agonist alone prescribed in case of uncontrolled asthma? Source: Annual Congress 2008 - Asthma: growing understanding of influential factors Year: 2008 Switching to maintenance and reliever inhaled corticosteroid/long acting beta agonist: a real-world pilot evaluation in a regional paediatric difficult asthma clinic. Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020 Is there a problem with inhaled corticosteroid use in COPD? Source: Virtual Congress 2020 – Airway diseases Year: 2020 Inhaled beta2-agonists in asthma management: an evolving story Source: Breathe 2016; 12: 375-377 Year: 2016 The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019 Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence? Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020 Identification of asthma level of control using administrative data of short-acting beta-agonist inhalers purchase Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 What to use INSTEAD of inhaled corticosteroids in COPD? Source: Eur Respir J 2014; 44: 1391-1393 Year: 2014 Cessation of long-acting beta2-agonist in children with persistent asthma on inhaled corticosteroids Source: Eur Respir J 2016; 48: 558-560 Year: 2016 Overuse of short-acting beta-agonists (SABA) and risk factors among patients with asthma Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma Source: Eur Respir J 2002; 20: Suppl. 38, 8s Year: 2002 Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Bronchodilator therapies for severe asthma Source: Eur Respir Mon 2011; 51: 253-267 Year: 2011 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015